Patient Outcomes: Sarilumab Beats Adalimumab
(MedPage Today) -- Pain, physical function, and health-related quality-of-life measures favored the IL-6 blocker (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 20, 2018 Category: Primary Care Source Type: news

Latest briefing on best value biological medicines (adalimumab) now available
A second update to regional Medicines Optimisation Committees (RMOCs) on the implementation of best value adalimumab “biosimilar” medicine products has recently been made available. (Source: NHS Networks)
Source: NHS Networks - June 18, 2018 Category: UK Health Source Type: news

FDA criticizes AbbVie for its handling of death complaints
The FDA reprimanded AbbVie in a recent report for not properly investigating death reports linked to three of its medications, including its blockbuster drug Humira. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 11, 2018 Category: Pharmaceuticals Source Type: news

Adalimumab Best on Costs in Ulcerative Colitis
(MedPage Today) -- Study conducted in Canada (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 5, 2018 Category: Gastroenterology Source Type: news

Regional Medicines Optimisation Committee (RMOC) briefing on adalimumab
NHS England Regional Medicines Optimisation Committee has published a briefing paper on adalimumab. The briefing provides a summary of advice on the next steps for commissioners and providers; practic (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news

Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod
ZURICH (Reuters) - Novartis's generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines. (Source: Reuters: Health)
Source: Reuters: Health - June 1, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Humira does not improve aortic vascular inflammation in psoriasis patients
(University of Pennsylvania School of Medicine) An antibody used to treat the skin disease psoriasis and other chronic autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease has no effect on aortic inflammation -- a key marker of future risk of major cardiovascular events -- unlike other antibodies that target different aspects of the immune system. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2018 Category: International Medicine & Public Health Source Type: news

Adalimumab Clears Nail Disease in Psoriatic Arthritis
(MedPage Today) -- Nail involvement often overlooked (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 2, 2018 Category: Dermatology Source Type: news

AbbVie's beat fueled by demand for Humira, Hep C drugs
(Reuters) - AbbVie Inc reported a better-than-expected quarterly profit on Thursday, driven by higher sales of its rheumatoid arthritis treatment Humira and its Hepatitis C drugs, leading the company to raise its full-year earnings forecast. (Source: Reuters: Health)
Source: Reuters: Health - April 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023 AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023
AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 6, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023
(Reuters) - AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023. (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie in deal with Samsung Bioepis to delay Humira biosimilar U.S. launch
(Reuters) - AbbVie Inc on Thursday said it signed a deal with Samsung Bioepis and its joint venture partner Biogen Inc that would fend off U.S. competition of their biosimilar version to blockbuster drug Humira until 2023. (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Samsung Bioepis
Agreements Provide Non-Exclusive License to Samsung Bioepis for HUMIRA-Related Intellectual Property in the U.S. Effective June 30, 2023, and in Other Markets on Different Dates Samsung Bioepis Acknowledges Validity of AbbVie's Intellectual Property for... Biopharmaceuticals, Litigation, Licensing AbbVie, Samsung Bioepis, biosimilar, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 5, 2018 Category: Pharmaceuticals Source Type: news

AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023
(Reuters) - AbbVie Inc on Thursday said it signed a deal with Biogen Inc and its joint venture partner Samsung Bioepis that would fend off U.S. competition of their rival version to blockbuster drug Humira until 2023. (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Adalimumab's Benefits Persist for Spine Disease
(MedPage Today) -- Improvements continued for clinical, functional, and MRI effects (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 28, 2018 Category: Primary Care Source Type: news

AbbVie's lung cancer drug data disappoints; shares slump
(Reuters) - AbbVie Inc's experimental lung cancer drug data was not effective enough to seek a faster approval, in a setback to the company's efforts to build its cancer drug pipeline and cut dependence on its blockbuster Humira. (Source: Reuters: Health)
Source: Reuters: Health - March 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Mark Stenhouse to join Exact Sciences as President, Cologuard
After leading HUMIRA sales and marketing to create a blockbuster drug, Abbott Laboratories/AbbVie executive to join Cologuard team MADISON, Wis., March 20, 2018 -- (Healthcare Sales & Marketing Network) -- Exact Sciences Corp. (Nasdaq: EXAS), the compa... Diagnostics, Oncology, Personnel Exact Sciences, Cologuard, colorectal cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 20, 2018 Category: Pharmaceuticals Source Type: news

Drug Spend Down in 2017, but Costs Still Up for Specialty Drugs Drug Spend Down in 2017, but Costs Still Up for Specialty Drugs
As in 2016, Humira was among most expensive drugs, but spending on hepatitis C therapies dropped precipitously.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 6, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Drug Costs Slowing Down, but Still High for Specialty Drugs Drug Costs Slowing Down, but Still High for Specialty Drugs
As in 2016, Humira was among most expensive drugs, but spending on hepatitis C therapies dropped precipitously.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 6, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Adalimumab dose escalation for UC treatment costly in Germany
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2018 Category: Drugs & Pharmacology Source Type: news

Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), submitted under the 351 (k) pathway, for proposed biosimilar adalimumab to the reference medicine, Humira®*. (Source: World Pharma News)
Source: World Pharma News - January 16, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Biological Therapies and Improvements in QoL in Psoriasis Biological Therapies and Improvements in QoL in Psoriasis
This study compared the effectiveness of adalimumab, etanercept and ustekinumab on improvements in HRQoL in patients with psoriasis. What factors are associated with these improvements?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Novartis advances head-to-head superiority trials of Cosentyx ® versus Humira®* and proposed biosimilar adalimumab**
Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS). SURPASS is the first head-to-head clinical trial in AS investigating superiority of Cosentyx in slowing spinal bone damage versus proposed biosimilar adalimumab**. SURPASS is currently recruiting patients, with the 'first patient first visit' already achieved in November 2017. (Source: World Pharma News)
Source: World Pharma News - January 9, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Morning Break: Pfizer Kills AD/PD Pipeline; Trump Affirms His Mental Health; Humira Pricing Strategy
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 8, 2018 Category: Primary Care Source Type: news

Humira ’ s Best-Selling Drug Formula: Start at a High Price. Go Higher.
AbbVie ’ s anti-inflammatory drug Humira was never cheap, selling for about $19,000 a year in 2012. It ’ s gone up by 100 percent since then. (Source: NYT Health)
Source: NYT Health - January 6, 2018 Category: Consumer Health News Authors: DANNY HAKIM Tags: vis-multimedia Drugs (Pharmaceuticals) Prices (Fares, Fees and Rates) Health Insurance and Managed Care Rheumatoid Arthritis AbbVie Inc Abbott Laboratories Source Type: news

Glenmark launches biosimilar Adalimumab in India
Glenmark did not give any financial detail for the drug, but globally Adalimumab is estimated to be a $16 billion drug in 2016, making it the "best" selling drug in the world. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 4, 2018 Category: Pharmaceuticals Source Type: news

Arthritis Drugs Show How US Drug Prices Defy Economics Arthritis Drugs Show How US Drug Prices Defy Economics
Wholesale prices for Humira and Enbrel, the two most commonly used treatments for rheumatoid arthritis, known as RA, increased more than 70 percent in the past three years.Kaiser Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 28, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Amjevita (adalimumab-atto) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 7, 2017 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim biosimilar candidate to Humira ® accepted for EMA and FDA regulatory review
Boehringer Ingelheim biosimilar candidate to Humira ® accepted for EMA and FDA regulatory review (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Sandoz says new clinical data support two biosimilars
ZURICH (Reuters) - Novartis' generics division, Sandoz, said new immunology data from four clinical studies supported its proposed biosimilars adalimumab for treating psoriasis and cancer drug rituximab. (Source: Reuters: Health)
Source: Reuters: Health - November 14, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Efficacy and safety maintained in patients who switched from Humira ® to biosimilar Cyltezo®
Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira®*. The 48-week data showed that Cyltezo® is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira® in people with moderately-to-severely active rheumatoid arthritis (RA), including in patients who switched from Humira® to Cyltezo® at week 24. (Source: World Pharma News)
Source: World Pharma News - November 6, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

One year data showing CYLTEZO is equivalent to HUMIRA
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 6, 2017 Category: Research Source Type: news

AbbVie says Humira sales will balloon to $21 billion in 2020, shares rise
(Reuters) - AbbVie Inc on Friday said it expects its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago. (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie tops estimates, predicts Humira sales to hit $21bn by 2020
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - October 27, 2017 Category: Pharmaceuticals Source Type: news

AbbVie says Humira sales will balloon to $21 billion in 2020
(Reuters) - AbbVie Inc on Friday forecast its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago. (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Asacol vs. Humira
Title: Asacol vs. HumiraCategory: MedicationsCreated: 10/6/2017 12:00:00 AMLast Editorial Review: 10/6/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 6, 2017 Category: Drugs & Pharmacology Source Type: news

Humira Again Top-Selling Drug In U.S.
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 4, 2017 Category: General Medicine Source Type: news

Humira Again Top-Selling Drug In U.S.
Title: Humira Again Top-Selling Drug In U.S.Category: Health NewsCreated: 10/4/2017 12:00:00 AMLast Editorial Review: 10/4/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - October 4, 2017 Category: Rheumatology Source Type: news

Humira Again Top-Selling Drug In U.S.
Popular anti-inflammatory leads list of top-selling drugs for fifth straight year. (Source: WebMD Health)
Source: WebMD Health - October 3, 2017 Category: Consumer Health News Source Type: news

AbbVie, Amgen settlement sets Humira U.S. biosimilar launch for 2023
(Reuters) - Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen's cheaper biosimilar version of AbbVie's cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the companies said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - September 28, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie makes peace with Amgen over Humira patents
(Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - September 28, 2017 Category: Pharmaceuticals Source Type: news

AbbVie Announces Global Resolution of HUMIRA(R) (adalimumab) Patent Disputes with Amgen
Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates Amgen Acknowledges Validity of AbbVie's Extensive Intellectual Property Portfolio for... Biopharmaceuticals, Generics, Litigation, Licensing AbbVie, Amgen, biosimilar, HUMIRA, adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2017 Category: Pharmaceuticals Source Type: news

Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA(TM)
Amgen to Begin Launching Biosimilar Adalimumab in Europe in 2018 THOUSAND OAKS, Calif., Sept. 28, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that it has reached a global settlement with AbbVie to resolve all ... Biopharmaceuticals, Generics, Litigation, Licensing Amgen, AbbVie, AMGEVITA, AMJEVITA, Humira, adalimumab, biosimilar (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 28, 2017 Category: Pharmaceuticals Source Type: news

Amgen And AbbVie Agree To Settlement Allowing Commercialization Of AMGEVITA ™
Amgen to Begin Launching Biosimilar Adalimumab in Europe in 2018 THOUSAND OAKS, Calif., Sept. 28, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has reached a global settlement with AbbVie to resolve all pending litigation regarding AMGEVITA™/AMJEVITA™, a biosimilar to AbbVie's Humira® (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of AMGEVITA/AMJEVITA worldwide, on a country-by-country basis, and the companies have agreed to dismiss all pending litigation. Amgen expects to launch AMGEVITA in Europe on Oct. 16, 2018, a...
Source: Amgen News Release - September 28, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

RA Activity Stable After Prolonging Adalimumab Interval RA Activity Stable After Prolonging Adalimumab Interval
Reducing the frequency of adalimumab did not worsen disease activity or function in patients with rheumatoid arthritis and may safely lower treatment costs and risks for adverse events, a study found.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 27, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news

RA Outcomes with Tocilizumab Surpass Those of Adalimumab, Methotrexate (CME/CE)
(MedPage Today) -- Benefits reflected in both physical and mental scores (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - September 25, 2017 Category: Rheumatology Source Type: news

Positive CHMP opinion for adalimumab biosimilar CYLTEZO
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 14, 2017 Category: Research Source Type: news

Cyltezo (Adalimumab-ADBM Injection, for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 8, 2017 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira ®
Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including: (Source: World Pharma News)
Source: World Pharma News - September 4, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news